There was a mention, I believe made by Rabin, I believe, that within a year, the commercial prospects, i.e. revenue for ACTC, will compare to and surpass Lipitor.
On the contrary, at yesterdays meeting he specifically stated that any significant revenues won't happen for "a couple of few years out" and that most likely will be with compassionate use, possibly in Europe. The commercial side of the money maker dryAMD(Lipitor numbers) are further out yet.